Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes.
Introduction
Treatment of symptoms commonly encountered by breast cancer survivors and quality of life have become significant and important considerations for medical oncologists. Hot flashes represent one of the most prominent complaints, encountered by approximately 55% of breast cancer survivors [1] . Hot flashes may be especially prominent in young women in whom adjuvant chemotherapy induces early menopause. Hot flashes may also be of concern for postmenopausal women in whom hormone replacement therapy is discontinued following a diagnosis of breast cancer.
A hot flash is a transient sensation of heat with or without objective signs of skin vasodilation and is often accompanied with varying degrees of sweating, flushing, palpitations, anxiety, irritability, and even panic [2] . Other commonly co-existing symptoms, such as depression, nervousness, agitation, insomnia, and inability to concentrate, may exacerbate hot flashes.
Estrogen replacement is the drug of choice for hot flashes [3] . Estrogen replacement therapy might be suitable to individual well-informed women with a prior breast cancer or in women at a high risk of developing the disease. However, this treatment is often avoided in this group of women due to the association between estrogen and breast cancer [4, 5] . In a randomized double-blind clinical trial, the progestin, megestrol acetate, reduced hot flashes in cancer survivors by 85% as compared to a 21% reduction in a placebo-controlled group [6] . However, due to a theoretical concern that low-dose progestin might increase the risk of developing a new breast cancer or a recurrence, this treatment is not as widely used as would otherwise be. Several nonhormonal agents have been reported to reduce hot flashes. These agents include Bellergal® (phenobarbital, ergotamine and belladonna), clonidine, vitamin E, and soy supplementation. However, prospective randomized clinical trials have demonstrated that these agents are only moderately more effective than placebo [7] [8] [9] [10] , and are associated with a high toxicity profile [7, 8] . Thus, a well-tolerated non-hormonal treatment for hot flashes would be of great value.
Selective serotonin-reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression. Anecdotal reports from our institution and others suggested that paroxetine hydrochloride (Paxil®, SmithKline Beecham Pharmaceuticals) and other SSRIs might be effective therapy for hot flashes. Based on our observation and the presumed physiology of hot flashes we initiated a single institution pilot study to evaluate whether paroxetine reduced the frequency and severity of hot flashes in breast cancer survivors. In a secondary analysis, we evaluated at baseline and at study end symptoms commonly associated with menopause. Specifically, we evaluated depression, sleep disruption, anxiety, sexual dysfunction, and overall quality of life (QOL).
Patients and methods

Subjects
Subjects eligible to participate in this pilot trial were women, 18 years or older, with a history of primary breast cancer who were without evidence of detectable disease. To be included in the study, women must have had a history of at least 14 hot flashes per week, for a period of at least 1 month, an ECOG performance status of 0-2, and a life expectancy of greater than 6 months. Women taking Tamoxifen were permitted on the study, as long as they had been taking the drug for at least one month prior to enrollment. Participants were not allowed to receive other simultaneous treatment for hot flashes, and were required to have discontinued other putative therapies for hot flashes for at least one month prior to enrollment. Because most of the breast cancer patients seen in our institution take many vitamin preparations, vitamin E was allowed, provided it was used regularly for at least six weeks prior to enrollment in the study, and was continued throughout the study period. Women were not eligible if they were receiving simultaneous cytotoxic chemotherapy, hormonal therapy other than Tamoxifen, or antidepressants. Women who were pregnant or lactating, or with a known severe renal or hepatic impairment, were excluded.
Prior to initiating the study, each woman underwent a history and physical. Laboratory studies included serum bilirubin and creatinine within six weeks prior to starting therapy, and a serum pregnancy test for all premenopausal women within two weeks prior to starting therapy. The study was approved by the Georgetown University's Institutional Review Board and participants signed informed consent prior to enrollment.
Study design
Thirty eligible women were included in the pilot trial. Prior to initiation of the study drug, each woman completed a daily diary for one week, and filled out a baseline symptom-assessment questionnaire and a linear QOL rating scale (EuroQOL survey) Each woman was then administered open-label paroxetine 10 mg a day ('A a tablet) for seven days, to assess side effects, especially somnolence. Then, the study participant started daily therapy with paroxetine 20 mg (one tablet) for four weeks. Paroxetine tablets sufficient for the treatment of 30 patients were provided by SmithKline Beecham Pharmaceuticals. The women completed daily diaries during the five weeks of drug therapy and repeated a symptom-assessment questionnaire and QOL scale during the sixth and final week of study. After completion of six weeks of study, the women returned the daily diaries, questionnaires, and any unused tablets by mail.
Daily diaries
The daily diaries of hot flash frequency and severity, as developed and described previously [6, 8, 9] , were used to document the number and severity (mild, moderate, severe, and very severe) of daily hot flashes for one week with no therapy (baseline) and throughout the five weeks of paroxetine therapy. In addition, the women documented presence or absence of four common adverse effects associated with paroxetine treatment (somnolence, dizziness, tremor, nausea). At the end of five weeks of treatment with the study drug, each woman was asked to assess whether she noted an overall subjective improvement in the hot flash symptoms, and whether she would like to continue the treatment.
Symptom-assessment questionnaire and quality of life scale
The symptom-assessment questionnaire was used to assess symptoms that are commonly associated with menopause and potential adverse effects to paroxetine. The questionnaire included a modified symptom checklist, that was developed for use in the National Surgical Adjuvant Breast and Bowel Project (NSABP) and used for phase II of the Women's Health Study [11] , the Center for Epidemiologic Studies Depression Scale (CES-D) [12] , the Medical Outcomes Study (MOS) 9-Item Sleep Scale [13] . the 7-item anxiety sub-scale items from the Hospital Anxiety and Depression Scale (HADS), a self-assessment scale designed to detect depression and anxiety in the setting of a hospital medical outpatient clinic [14] , and a 4-item scale of sexual function from the MOS [13] . To measure overall health-related QOL, we used the format standardized in the EuroQOL survey, a self-rating scale that is reliable, valid, brief and easy to administer [15.16] .
Statistical considerations
The sample size of 30 patients provided 80% power (one-sided test; a = 0.05) to detect a 50% reduction in hot flashes at week 6. A planned comparison was made to the 20%-27% reduction in hot flash frequency and severity observed as a placebo effect in previous randomized trials of anti-hot flash therapy in similar patient populations [6, 8. 9 ]. The power calculation was based on the assumption that the percent reduction in hot flashes was approximately normally distributed with SD = 45%
Box plots of the data indicated that the percent reduction in hot flashes (using the baseline week as a reference) was approximately normally distributed. Applying simple transformations to the endpoint (e.g., taking the logarithm or square root) was unhelpful, and actually worsened the normal approximation. A one-sample, two-tail /-test was conducted to determine whether the percent reduction in hot flashes at week 6 was significantly better than 27%.
Severity of hot flash symptoms was an important endpoint. Weekly Severity Score was calculated as: 1 x (incidence count of 'mild' hot flashes experienced during one week) + 2 x ("moderate' hot flashes) + 3 x ('severe' hot flashes) + 4 x ('very severe' hot flashes) [6] . We computed the ratio of severity score at week 6 to severity score at baseline, and conducted a one-sample /-test to determine whether the mean reduction in severity score was greater than the expected placebo effect.
Menopause-related symptoms and QOL data were analyzed in a similar manner. However, since some patients had baseline depression and anxiety scores of zero, it would have been inappropriate to use percentage change from baseline. Instead, the effect of paroxetine on QOL was based on the simple difference in score between week 6 and week 1. For symptoms that were dichotomous (present/absent), the change between baseline and week 6 was analyzed using McNemar's test. All tests were two-sided and /'-values less than 0.05 were considered statistically significant. 
Results
Patients
From November 1997, through June 1998, 30 eligible women entered the pilot trial. Twenty-seven women completed the six-week study and were evaluable for drug efficacy. Three women discontinued drug therapy due to adverse effects. All 30 patients were evaluable for safety and tolerability. The patients' characteristics are summarized in Table 1 . Mean number of daily hot flashes prior to treatment was 8 (range 2.1-21). Mean severity score prior to treatment was 134 (range 29-361).
Reduction of hot flashes
Of the 27 women who completed the trial, the mean reduction of hot flashes at week six was 67% with a 95% confidence interval (95% CI) of 56%-79% (Figure 1 ). Of the 30 women included in the study, 20 women (67%) reported a greater than 50% reduction in the average daily number of hot flashes. The mean reduction of hot flashes suggested a significant improvement over the previously reported 20%-27% reduction in hot flashes seen as a placebo-effect in similar patient populations (P < 0.0001) [6, 8, 9] . In addition, of the 26 women who completed the trial and severity score questionnaires, the mean reduction in hot flash severity scores at week 6 was 75% (95% CI: 66%-85%, Figure 2 ). Overall, of the 30 women included in the study, 22 women (73%) noted a greater than 50% reduction in hot flash severity scores. Furthermore, 25 (83%) of the women who entered the study chose to continue paroxetine therapy at the end of the trial period.
The sample size was too small to assess differences in response among women who have undergone natural versus chemotherapy-induced menopause, or among women who were on Tamoxifen therapy versus not. Nonetheless, there did not appear to be any obvious differences in these groups.
Safety and tolerability
Adverse effects were minimal and included mostly somnolence (Table 2) . Two patients discontinued drug therapy due to excessive somnolence following three days, and seventeen days, respectively, of drug therapy. One patient discontinued the drug following twenty-three days of therapy due to anxiety. Two patients decreased their paroxetine dose to 10 mg due to somnolence encountered on the higher dose. 
Symptom-assessment questionnaire and quality of life scale
Thirty women completed symptom assessment and QOL questionnaires at baseline and twenty-seven women completed the questionnaires during week 6. Overall, following five weeks of paroxetine therapy, there was an improvement in the five most common menopausal symptoms encountered by the women included in this study at baseline (short temper, forgetfulness, headaches, vaginal dryness, and difficulties concentrating). However, the differences in menopausal symptoms prior to and following paroxetine therapy were not statistically significant (data not shown). In addition, up to 18 (66%) of the women noted worsening of symptoms that could be contributed to paroxetine (somnolence, dry mouth, nausea, constipation, and decreased appetite).
There was an improvement in depression, sleep, anxiety, and QOL measures (Table 3) . At baseline, six (20%) women had CES-D scores consistent with a depressive state (2* 16), and two (7%) had HADS scores consistent with anxiety (Js 11). None of the three women who failed to complete the second set of questionnaires were depressed or anxious at baseline. Following five weeks of therapy, only two (7%) women had CES-D scores consistent with a depressive state, and none had HADS scores consistent with anxiety. At week 6, the mean improvement in depression, anxiety, and sleep scores was 4.2 (95% CI: 0.7-7.6), 1.8 (95% CI: 0.9-2.7), (10) 3 (10) 3 (10) a Subjective complaint, not included in initial questionnaire, thus, data not available. and 14.6 (95% CI: 6.4-22.8), respectively. The mean improvement in QOL score was 5.9 (95% CI: 2.1-9.7). The effect of paroxetine was significantly different from zero for all four measures (depression, P = 0.02; anxiety, P = 0.0005; sleep, P = 0.0002; QOL, P = 0.004). Only 17 (57%) women completed the sexual function scale. The effect of paroxetine on sexual function was inconclusive perhaps due to the minimal effect in this domain or the smaller number of women reporting on function.
Discussion
In this study, we observed a substantial reduction in hot flashes following five weeks of treatment with paroxetine hydrochloride (Paxil®) in a group of women with a previous diagnosis of breast cancer. Although this was a pilot study, the 67% reduction in hot flash frequency we observed appears superior to the 20-27% reduction observed with placebo in other trials [6, 8, 9] . This large difference suggests that the beneficial effects in the trial were not due to placebo-effect.
Paroxetine was generally well tolerated with the most commonly reported adverse effect being somnolence. An improvement in menopausal symptoms, depression, anxiety, and sleep was seen in most of the women. Moreover, there was a substantial improvement in median scores of QOL.
The physiology of hot flashes is probably related to dysfunction of the thermoregulation set point [2] . Investigators have suggested that estrogen-withdrawal results in decreased levels of brain amines, such as serotonin [17] . This hypothesis might explain why estrogen withdrawal is associated not only with hot flashes, but also with alterations in sleep, anxiety and mood. Other investigators have demonstrated that blood levels of serotonin are diminished in menopausal women [18] . Moreover, estrogen replacement therapy appears to augment serotonergic activity [19] . The beneficial results observed in our study are consistent with the theory that SSRIs might be an effective therapy for hot flashes and associated perimenopausal symptoms.
Recently, other investigators have reported results of a pilot evaluation of the SSRI venlafaxine hydrochloride in breast cancer survivors and in men on androgenblockade [20] . These results are markedly similar to our observations. The authors reported that 55% of the subjects included in the study had a greater than 50% reduction in hot flash frequency and 58% had a greater than 50% reduction in hot flash severity scores. However, both studies are pilot trials, and are limited by small sample size and lack of a concomitant placebo arm.
This pilot trial cannot answer questions related to the optimal dose of treatment. For example, many of the study participants noted an almost immediate reduction in the frequency and severity of their hot flashes. It is therefore possible that a dose of paroxetine 10 mg daily might be sufficient in alleviating hot flashes. Also, it is possible that women who did not respond to the standard antidepressant dose of 20 mg might benefit from an increased paroxetine dose. The pilot study was not sufficiently powered to detect differences in benefit between various subgroups, such as women who suffered long versus short duration of hot flashes, younger or older women. Moreover, the pilot study does not have sufficient power to detect differences in improvement of hot flashes in women who are on Tamoxifen therapy versus these who were not, or in women who underwent natural menopause as compared to chemotherapy-induced menopause. Finally, optimal duration of treatment was also not established. Many women who suffer severe hot flashes immediately following menopause might experience an improvement over time without therapy. Of interest in this study is the large number of women who continued medication at the end of the study.
In summary, the data from this pilot trial strongly suggest that paroxetine hydrochloride is an effective therapy for hot flashes in breast cancer survivors. We are now conducting a prospective randomized clinical trial to determine the effectiveness of paroxetine hydrochloride in reducing hot flashes as compared to placebo.
